Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) Invested Capital (2016 - 2025)

Historic Invested Capital for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $180.1 million.

  • Abeona Therapeutics' Invested Capital rose 25868.73% to $180.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.1 million, marking a year-over-year increase of 25868.73%. This contributed to the annual value of $50.0 million for FY2024, which is 23695.53% up from last year.
  • Abeona Therapeutics' Invested Capital amounted to $180.1 million in Q3 2025, which was up 25868.73% from $169.1 million recorded in Q2 2025.
  • Abeona Therapeutics' Invested Capital's 5-year high stood at $180.1 million during Q3 2025, with a 5-year trough of -$8.9 million in Q1 2024.
  • In the last 5 years, Abeona Therapeutics' Invested Capital had a median value of $47.0 million in 2021 and averaged $58.5 million.
  • The largest annual percentage gain for Abeona Therapeutics' Invested Capital in the last 5 years was 70752.27% (2024), contrasted with its biggest fall of 14739.06% (2024).
  • Over the past 5 years, Abeona Therapeutics' Invested Capital (Quarter) stood at $47.0 million in 2021, then tumbled by 43.02% to $26.8 million in 2022, then crashed by 44.6% to $14.8 million in 2023, then soared by 236.96% to $50.0 million in 2024, then skyrocketed by 260.55% to $180.1 million in 2025.
  • Its Invested Capital was $180.1 million in Q3 2025, compared to $169.1 million in Q2 2025 and $49.5 million in Q1 2025.